A is the answer and the winners are Maryam and Solace.
Details Below:
Atenolol is a cardioselective beta-adrenoceptor blocker that is used in hyper-
tension and in angina. The recommended daily dose for atenolol in hyper-
tension is 25–100 mg, although the 50 mg dose is usually adequate. As a
beta-blocker it may mask symptoms of hypoglycaemia. However, this is of no
concern in AB as the patient is not taking any antidiabetic agents but is control-
ling diabetes through diet. Beta-blockers have negative inotropic properties
and therefore may cause bradycardia and they should not be used in patients
with uncontrolled heart failure. Treatment with beta-blockers such as atenolol
should be started with care in patients with heart failure. It has been demon-
strated that three beta-blockers namely bisoprolol, carvedilol, and metoprolol
reduce heart failure disease progression, decrease symptoms and mortality
when used in stable heart failure. In AB it is an option to consider changing
atenolol to an alternative therapeutic approach which better tackles the
concomitant occurrence of hypertension and congestive heart failure. Use of
one of these three beta-blockers (bisoprolol, carvedilol, and metoprolol) is an
option.
generic drugs without doctor’s prescription: https://genericwdp.com/ generic pills without a doctor prescription
buy tadalafil: http://tadalafilonline20.com/ tadalafil daily use
A is the answer and the winners are Maryam and Solace.
Details Below:
Atenolol is a cardioselective beta-adrenoceptor blocker that is used in hyper-
tension and in angina. The recommended daily dose for atenolol in hyper-
tension is 25–100 mg, although the 50 mg dose is usually adequate. As a
beta-blocker it may mask symptoms of hypoglycaemia. However, this is of no
concern in AB as the patient is not taking any antidiabetic agents but is control-
ling diabetes through diet. Beta-blockers have negative inotropic properties
and therefore may cause bradycardia and they should not be used in patients
with uncontrolled heart failure. Treatment with beta-blockers such as atenolol
should be started with care in patients with heart failure. It has been demon-
strated that three beta-blockers namely bisoprolol, carvedilol, and metoprolol
reduce heart failure disease progression, decrease symptoms and mortality
when used in stable heart failure. In AB it is an option to consider changing
atenolol to an alternative therapeutic approach which better tackles the
concomitant occurrence of hypertension and congestive heart failure. Use of
one of these three beta-blockers (bisoprolol, carvedilol, and metoprolol) is an
option.
B
B
B
A
A
A